- Eli Lilly And Co (NYSE: LLY) have announced topline results from two Phase 3 studies, SURPASS-3 and SURPASS-5, evaluating Tirzepatide in adults with type 2 diabetes. Data showed that Tirzepatide led to significant A1C and body weight reductions from baseline after 52 (SURPASS-3) weeks and 40 (SURPASS-5) weeks, respectively.
- Using the efficacy estimand, the highest dose of tirzepatide (15 mg) reduced A1C by 2.37% and body weight by 12.9 kg (13.9%) in SURPASS-3, and reduced A1C by 2.59% and body weight by 10.9 kg (11.6%) in SURPASS-5.
- At the highest dose, 62.4% of SURPASS-5 participants achieved an A1C of less than 5.7%, the level seen in people without diabetes.
- In both studies, the overall safety profile of tirzepatide was similar to that of the well-established glucagon-like peptide-1 (GLP-1) receptor agonist class, with gastrointestinal side effects being the most commonly reported adverse events and decreasing with continued dosing.
- Tirzepatide is an investigational once-weekly dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist that integrates both incretins' actions into a single molecule.
- SURPASS-3 was a 52-week trial comparing the efficacy and safety of three doses of tirzepatide (5 mg, 10 mg, and 15 mg) to titrated insulin degludec in adults with type 2 diabetes who have inadequate glycemic control on stable doses of metformin with or without an SGLT-2 inhibitor.
- SURPASS-5 was a 40-week trial comparing the efficacy and safety of three doses of tirzepatide (5 mg, 10 mg, and 15 mg) compared to placebo, both as an add-on to titrated insulin glargine with or without metformin in adults with type 2 diabetes.
- The complete SURPASS-3 and SURPASS-5 data have not yet been evaluated but will be presented at the American Diabetes Association's 81st Scientific Sessions and published in a peer-reviewed publication in 2021.
- Price Action: LLY stock increased 1.1% at $208 in premarket trading on the last check Wednesday.
Loading...
Loading...
LLYEli Lilly and Co
$733.142.46%
Edge Rankings
Momentum
34.15
Growth
82.20
Quality
85.57
Value
3.27
Price Trend
Short
Medium
Long
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
